FEMASYS INCFEMYEarnings & Financial Report
Femasys Inc. is a medical technology firm specializing in developing and commercializing minimally invasive diagnostic and therapeutic devices for women's health. Its core products address unmet clinical needs in fertility care, gynecology and obstetrics, serving healthcare providers and patients mainly across North American and European markets.
FEMY Q4 FY2025 Key Financial Metrics
Revenue
$813.4K
Gross Profit
$510.3K
Operating Profit
$-4.6M
Net Profit
$-4.0M
Gross Margin
62.7%
Operating Margin
-568.3%
Net Margin
-485.7%
YoY Growth
39.9%
EPS
$0.02
FEMASYS INC Q4 FY2025 Financial Summary
FEMASYS INC reported revenue of $813.4K (up 39.9% YoY) for Q4 FY2025, with a net profit of $-4.0M (up 22.9% YoY) (-485.7% margin). Cost of goods sold was $303.1K, operating expenses totaled $5.1M.
Key Financial Metrics
| Total Revenue | $813.4K |
|---|---|
| Net Profit | $-4.0M |
| Gross Margin | 62.7% |
| Operating Margin | -568.3% |
| Report Period | Q4 FY2025 |
FEMASYS INC Annual Revenue by Year
FEMASYS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.3M).
FEMASYS INC Quarterly Revenue & Net Profit History
FEMASYS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $813.4K | +39.9% | $-4.0M | -485.7% |
| Q3 FY2025 | $729.4K | +31.4% | $-4.2M | -575.1% |
| Q2 FY2025 | $409.3K | +84.8% | $-4.6M | -1120.5% |
| Q1 FY2025 | $341.3K | +25.9% | $-5.9M | -1727.9% |
| Q4 FY2024 | $581.6K | +172.9% | $-5.1M | -881.0% |
| Q3 FY2024 | $554.9K | +127.1% | $-5.4M | -974.7% |
| Q2 FY2024 | $221.5K | -30.9% | $-4.7M | -2115.1% |
| Q1 FY2024 | $271.1K | -7.8% | $-3.6M | -1327.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $271140 | $221484 | $554908 | $581576 | $341264 | $409268 | $729394 | $813387 |
| YoY Growth | -7.8% | -30.9% | 127.1% | 172.9% | 25.9% | 84.8% | 31.4% | 39.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $24.4M | $20.3M | $15.6M | $12.4M | $13.3M | $13.8M | $16.3M | $20.7M |
| Liabilities | $8.8M | $9.0M | $9.6M | $10.1M | $11.3M | $12.3M | $11.7M | $14.9M |
| Equity | $15.6M | $11.3M | $6.0M | $2.3M | $2.0M | $1.5M | $4.6M | $5.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.6M | $-4.3M | $-5.5M | $-5.1M | $-4.8M | $-4.4M | $-5.4M | $-4.2M |